X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AB-2100, an engineered ICT cell therapy, is presently undergoing evaluation in Phase 1/2 clinical trial studies with patients for treating clear-cell renal cell carcinoma.
Lead Product(s): AB-2100
Therapeutic Area: Oncology Product Name: AB-2100
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
AB-1015 is ArsenalBio’s first internally discovered T cell medicine to enter clinical development and uses synthetic DNA programming to overcome tumor defenses, increase potency, and target ovarian cancer cells without harming normal tissues.
Lead Product(s): AB-1015
Therapeutic Area: Oncology Product Name: AB-1015
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Under the terms of the collaboration, ArsenalBio and Genentech will deploy synergistic capabilities to study effective T cell-based modifications and develop new understandings of their effects through preclinical analysis.
Lead Product(s): T-cell Based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Genentech
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Collaboration September 27, 2022
Details:
The fundraising comes as the company begins planning for clinical trials of its lead program AB-1015, an ovarian cancer candidate for which FDA IND clearance and first patient dosing are targeted for later this year.
Lead Product(s): AB-1015
Therapeutic Area: Oncology Product Name: AB-1015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Softbank Vision Fund 2
Deal Size: $220.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 06, 2022
Details:
ArsenalBio will deploy its full stack of synthetic biology compositions to build programmable cell therapy product candidates, composed of its PrimeR™ logic gates, CARchitecture™ derived gene expression controls, and CellFoundry™ mediated nonviral manufacturing.
Lead Product(s): Next-generation T cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Collaboration January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
